Who is sponsoring NCT05028439?

NCT05028439 is sponsored by First People's Hospital of Hangzhou.

What condition does NCT05028439 study?

NCT05028439 studies Cholangiocarcinoma.

What drugs are being tested in NCT05028439?

Interventions: radiofrequency ablation, Chemotherapy drug.

What is the status of NCT05028439?

NCT05028439 is currently COMPLETED.

Last reviewed 2023-02-21 · How we verify

RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma

NCT05028439 NA COMPLETED

Extrahepatic cholangiocarcinoma is a malignant tumor that is highly malignant and difficult to diagnose and treat early. Endobiliary radiofrequency ablation (RFA) has been reported to be a beneficial treatment option for palliation of malignant biliary strictures. Within the bile duct, RFA appears to be safe and may result in decreased tumor ingrowth. To date, little is known about the role of the addition of systemic chemotherapy to RFA for cholangiocarcinoma. The aim of this study is to compare the efficacy and safety of RAF combined with Gemcitabine and S-1 in patients with unresectable cholangiocarcinoma.

Details

Lead sponsor	First People's Hospital of Hangzhou
Phase	NA
Status	COMPLETED
Enrolment	70
Start date	Wed Jan 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Cholangiocarcinoma

Interventions

radiofrequency ablation
Chemotherapy drug

Countries

China